{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:21:47Z","timestamp":1792855307172,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bimekizumab, a monoclonal antibody targeting both interleukin-17A and interleukin-17F, has shown strong efficacy in moderate-to-severe plaque psoriasis. However, long-term real-world data on its effectiveness and treatment persistence remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the 2-year drug survival of bimekizumab in a real-life setting across multiple Italian dermatology centres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre, retrospective, observational study included adult patients with moderate-to-severe plaque psoriasis who initiated bimekizumab between May 2022 and November 2024. Drug survival was assessed using Kaplan\u2013Meier analysis. Univariable and multivariable Cox regression models were used to identify predictors of treatment persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 826 patients were included (66.6% male; mean age 52.3\u2005years, SD 14.9). At baseline, the mean Psoriasis Area and Severity Index (PASI) score was 15.5 (SD 8.9), which decreased to 1.4 (3.3) at the last follow-up. Estimated drug survival rates at 12, 18 and 24\u2005months were 89.1%, 85.0% and 82.4%, respectively. In total, 129 patients discontinued treatment, primarily due to adverse events (n = 68) and ineffectiveness (n = 31). In both univariable and multivariable analyses, male sex was significantly associated with a lower risk of discontinuation (hazard ratio 0.65, P = 0.002 and hazard ratio 0.67, P = 0.008, respectively). Other factors, including body mass index (BMI) &amp;gt; 30\u2005kg m\u22122, presence of psoriatic arthritis, baseline PASI &amp;gt; 15 and prior biologic exposure, were not significantly associated with treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world study demonstrates the long-term effectiveness and high drug survival of bimekizumab up to 24\u2005months, across diverse patient profiles, regardless of BMI, disease severity, prior biologic exposure or presence of psoriatic arthritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag021","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:36:18Z","timestamp":1768048578000},"page":"1028-1033","source":"Crossref","is-referenced-by-count":7,"title":["Long-term effectiveness of bimekizumab in plaque psoriasis: 2-year drug survival from a real-life multicentre Italian study"],"prefix":"10.1093","volume":"51","author":[{"given":"Eleonora","family":"De Luca","sequence":"first","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli \u2013 IRCCS , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular Sciences, La Sapienza University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Artosi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Rome Tor Vergata, Department of Systems Medicine , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bellinato","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Dermatology and Venereology, University of Verona , Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Rome Tor Vergata, Department of Systems Medicine , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[{"name":"Section of Dermatology, DISSAL, University of Genoa, IRCCS Ospedale Policlinico San Martino , 16044 Genova ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campione","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Rome Tor Vergata, Department of Systems Medicine , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Francesca","family":"Cavaliere","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica AOU Policlinico Consorziale Bari \u2013 Universit\u00e0 Degli Studi di Bari \u2018A. Moro\u2019 , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele\u00a0Claudio","family":"Cozzani","sequence":"additional","affiliation":[{"name":"Section of Dermatology, DISSAL, University of Genoa, IRCCS Ospedale Policlinico San Martino , 16044 Genova ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele , 20072 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gaiani","sequence":"additional","affiliation":[{"name":"Centro Psocare, IRCCS Policlinico San Donato Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele , 20072 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Dermatology and Venereology, University of Verona , Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia\u00a0Finistauri","family":"Guacci","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular Sciences, La Sapienza University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Guarino","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular Sciences, La Sapienza University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica AOU Policlinico Consorziale Bari \u2013 Universit\u00e0 Degli Studi di Bari \u2018A. Moro\u2019 , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[{"name":"Centro Psocare, IRCCS Policlinico San Donato Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Mianulli","sequence":"additional","affiliation":[{"name":"Centro Psocare, IRCCS Policlinico San Donato Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Messina","sequence":"additional","affiliation":[{"name":"Centro Psocare, IRCCS Policlinico San Donato Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele , 20072 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7997-1784","authenticated-orcid":false,"given":"Nello","family":"Tommasino","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italian","family":"Landscape Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli \u2013 IRCCS , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli \u2013 IRCCS , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-9232","authenticated-orcid":false,"given":"Giacomo","family":"Caldarola","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli \u2013 IRCCS , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"2026052522572975000_llag021-B1","doi-asserted-by":"crossref","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026052522572975000_llag021-B2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaad.2023.08.097","article-title":"Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry","volume":"90","author":"Strober","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572975000_llag021-B3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"2026052522572975000_llag021-B4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2028","journal-title":"Ann Rheum Dis"},{"key":"2026052522572975000_llag021-B5","doi-asserted-by":"crossref","first-page":"e20202345","DOI":"10.1084\/jem.20202345","article-title":"Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis","volume":"218","author":"Nakamizo","year":"2021","journal-title":"J Exp Med"},{"key":"2026052522572975000_llag021-B6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","article-title":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial","volume":"89","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572975000_llag021-B7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"2026052522572975000_llag021-B8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2026052522572975000_llag021-B9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"2026052522572975000_llag021-B10"},{"key":"2026052522572975000_llag021-B11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14712598.2023.2193288","article-title":"Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study","volume":"23","author":"Caldarola","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2026052522572975000_llag021-B12","doi-asserted-by":"crossref","first-page":"e2024152","DOI":"10.5826\/dpc.1402a152","article-title":"Long-term effectiveness of brodalumab for the treatment of moderate-to-severe psoriasis: a real-life multicenter study of up to 3\u2005years in a real-life Italian cohort","volume":"14","author":"Caldarola","year":"2024","journal-title":"Dermatol Pract Concept"},{"issue":"Suppl. 3","key":"2026052522572975000_llag021-B13","first-page":"iii50","article-title":"The 1-year all-cause drug survival of bimekizumab compared with other biologics in psoriasis: a nationwide real-world cohort study","volume":"191","author":"Schwarz","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026052522572975000_llag021-B14","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s13555-024-01257-2","article-title":"Impact of disease burden of patients with psoriasis on biologic therapy switching: real-world evidence from the CorEvitas psoriasis registry","volume":"14","author":"Blauvelt","year":"2024","journal-title":"Dermatol Ther"},{"key":"2026052522572975000_llag021-B15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00403-024-03594-w","article-title":"Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study","volume":"317","author":"Potestio","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"2026052522572975000_llag021-B16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jaad.2024.12.034","article-title":"Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: a 52-week multicenter retrospective review","volume":"92","author":"Sood","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572975000_llag021-B17","doi-asserted-by":"crossref","first-page":"2432932","DOI":"10.1080\/09546634.2024.2432932","article-title":"Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics","volume":"36","author":"Mortato","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"2026052522572975000_llag021-B18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/1346-8138.17532","article-title":"Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: a 52-week real-world study","volume":"52","author":"Hagino","year":"2025","journal-title":"J Dermatol"},{"key":"2026052522572975000_llag021-B19","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1007\/s13555-024-01302-0","article-title":"Long-term efficacy and safety of bimekizumab and other biologics in moderate to severe plaque psoriasis: updated systematic literature review and network meta-analysis","volume":"14","author":"Warren","year":"2024","journal-title":"Dermatol Ther"},{"key":"2026052522572975000_llag021-B20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2025.04.038","article-title":"Bimekizumab durability of efficacy through 196 weeks and safety through 4\u2005years in patients with moderate to severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","volume":"93","author":"Blauvelt","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572975000_llag021-B21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3\u2005years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","volume":"188","author":"Strober","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026052522572975000_llag021-B22","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/ced\/llaf271","article-title":"Predictive factors of eczematous eruptions and candidiasis during anti IL-17 treatment in psoriatic patients: a multicenter Italian real-life experience in Lazio region","volume":"50","author":"Caldarola","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026052522572975000_llag021-B23","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s13555-025-01435-w","article-title":"Gender influence on bimekizumab response in patients with psoriasis: results of a real-world multicenter retrospective study \u2013 IL PSO (Italian Landscape PSOriasis)","volume":"15","author":"Gioacchini","year":"2025","journal-title":"Dermatol Ther"},{"key":"2026052522572975000_llag021-B24","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/rheumatology\/key140","article-title":"Gender differences in biologic treatment outcomes \u2013 a study of 1750 patients with psoriatic arthritis using Danish health care registers","volume":"57","author":"H\u00f8jgaard","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026052522572975000_llag021-B25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/bjd.20710","article-title":"Systemic antipsoriatic treatment: do women respond better than men and if so, why?","volume":"185","author":"Wolf","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026052522572975000_llag021-B26","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/ced\/llae147","article-title":"Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced","volume":"49","author":"Megna","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026052522572975000_llag021-B27","doi-asserted-by":"crossref","first-page":"1243843","DOI":"10.3389\/fmed.2023.1243843","article-title":"Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study \u2013 IL PSO (Italian landscape psoriasis)","volume":"10","author":"Gargiulo","year":"2023","journal-title":"Front Med"},{"key":"2026052522572975000_llag021-B28","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1111\/ijd.17927","article-title":"Effectiveness of bimekizumab in psoriatic arthritis: a multicenter real-life study with clinical and ultrasound evaluation in the Lazio region, Italy","volume":"64","author":"Caldarola","year":"2025","journal-title":"Int J Dermatol"},{"key":"2026052522572975000_llag021-B29","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.5826\/dpc.1501a4893","article-title":"Real-life experience of bimekizumab in 27 obese patients with plaque-type psoriasis: a 24-week multicenter retrospective study","volume":"15","author":"Fratton","year":"2025","journal-title":"Dermatol Pract Concept"},{"key":"2026052522572975000_llag021-B30","doi-asserted-by":"crossref","first-page":"103577","DOI":"10.1016\/j.autrev.2024.103577","article-title":"Global prevalence of obesity in patients with psoriasis: an analysis in the past two decades","volume":"23","author":"Wang","year":"2024","journal-title":"Autoimmun Rev"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag021\/66387235\/llag021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1028\/66387235\/llag021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1028\/66387235\/llag021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:57:38Z","timestamp":1779764258000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/6\/1028\/8424102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag021","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,1,13]]}}}